New drug combo aims to stop aggressive breast cancer from returning
NCT ID NCT07622836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy after surgery can help prevent high-risk triple-negative breast cancer from coming back. About 59 women with this aggressive cancer type will receive the combination treatment, followed by maintenance QL1706 alone. The main goal is to see how many women remain cancer-free three years later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (a combination of two antibodies, Aipaluoli and tovorilimab) plus AC-T chemotherapy
What this could lead to
If successful, this could offer a more effective post-surgery treatment option for people with high-risk triple-negative breast cancer, potentially reducing the chance of the cancer coming back.
What could go wrong
This is a small, early-phase (Phase II) trial with only 59 participants, so results may not apply to everyone. The treatment combines chemotherapy with an immunotherapy drug, which can cause significant side effects, and it's not yet known if it will improve long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact